KRAS and neoplasm: Therefore, in this study, the landscapes of immune checkpoints, cytolytic activity signature, IFN-γ signature, and somatic mutations were further investigated in the two types, and significantly different immune activities were observed between them, which indicated the differences in intrinsic tumor immunogenicity, while a higher mutation frequency of KRAS and TP53 was observed in the SRS-high group.